RSNA 2019 Women's Imaging Preview

BI-RADS 3 means biopsy with prior breast cancer history

By Kate Madden Yee, staff writer

November 5, 2019 --

Sunday, December 1 | 1:00 p.m.-1:30 p.m. | BR259-SD-SUB4 | Lakeside, BR Community, Station 4
For women with a prior history of breast cancer, a BI-RADS 3 finding should prompt biopsy, according to research that will be presented on Sunday afternoon in the Lakeside Learning Center.

Presenter Dr. Wendie Berg, PhD, of the University of Pittsburgh School of Medicine, will share findings from a study that explored how women with a personal history of breast cancer and who had BI-RADS 3 lesions should be followed, using data from the National Mammography Database (NMD) to assess the cancer yield of these lesions. The study included nearly 68,000 women with BI-RADS 3 findings identified between 2009 and 2018 from 471 NMD facilities; Berg's group tracked the positive predictive value of biopsies (PPV3) and the number of breast cancers per number of women (cancer yield).

Of all the women included in the study, 3.1% had a personal history of breast cancer. For these women, the overall biopsy rate of BI-RADS 3 lesions was 26.1%, yielding 339 cancers; the PPV3 of these biopsies was 62.2%. Overall cancer yield among women with a personal history of breast cancer was 16.2% -- far beyond the rate of 1.34% among women who do not have a history of the disease, Berg's group noted.

"Imaging findings that would otherwise be considered BI-RADS 3 in average-risk women should generally prompt biopsy in woman with personal history of breast cancer," Berg and colleagues concluded.